Joseph Biederman1, Maura Fitzgerald2, K Yvonne Woodworth2, Amy Yule3, Elizabeth Noyes2, Itai Biederman2, Stephen V Faraone4, Timothy Wilens3, Janet Wozniak3. 1. Pediatric Psychopharmacology and Adult ADHD, Massachusetts General Hospital, Boston, MA, USA; Department of Psychiatry, Harvard Medical School, Boston, MA, USA. Electronic address: jbiederman@partners.org. 2. Pediatric Psychopharmacology and Adult ADHD, Massachusetts General Hospital, Boston, MA, USA. 3. Pediatric Psychopharmacology and Adult ADHD, Massachusetts General Hospital, Boston, MA, USA; Department of Psychiatry, Harvard Medical School, Boston, MA, USA. 4. Department of Psychiatry and of Neuroscience and Physiology, SUNY Upstate Medical University, Syracuse, NY, USA; K.G. Jebsen Centre for Psychiatric Disorders, Department of Biomedicine, University of Bergen, Bergen, Norway.
Abstract
BACKGROUND: To assess whether the course of pediatric bipolar-I (BP-I) disorder impacts the course of conduct disorder (CD)/antisocial personality disorder (ASPD). We hypothesized that remission of manic symptoms in BP-I youth will be associated with remission of CD/ASPD. METHODS: We used data from four longitudinal datasets of carefully characterized and comprehensively assessed youth with structured diagnostic interview based diagnoses of BP-I disorder and CD/ASPD assessed at baseline in childhood and at follow-up onto adolescent years. The baseline sample consisted of 240 subjects with full BP-I disorder. The average follow-up time was 6.6 ± 2.4 years. RESULTS: Subjects with remitting BP-I disorder in adolescent years had a significantly lower one-year prevalence of CD or ASPD compared to those with persistent BP-I disorder (χ2 = 10.35, p = 0.001). LIMITATIONS: Our inferences were derived from the examination of naturalistic longitudinal follow-up data and not results of a clinical trial. CONCLUSIONS: Results indicate that remission of manic symptoms at the adolescent follow up in youth with BP-I disorder were associated with a significant decrease in rates of CD/ASPD. These results suggest that targeting manic symptoms in youth with BP-I disorder could mitigate the course of CD/ASPD in youth. Considering the high morbidity and disability associated CD/ASPD in youth and the limited treatment options available to address it, if replicated, these findings would have very important clinical and public health significance.
BACKGROUND: To assess whether the course of pediatric bipolar-I (BP-I) disorder impacts the course of conduct disorder (CD)/antisocial personality disorder (ASPD). We hypothesized that remission of manic symptoms in BP-I youth will be associated with remission of CD/ASPD. METHODS: We used data from four longitudinal datasets of carefully characterized and comprehensively assessed youth with structured diagnostic interview based diagnoses of BP-I disorder and CD/ASPD assessed at baseline in childhood and at follow-up onto adolescent years. The baseline sample consisted of 240 subjects with full BP-I disorder. The average follow-up time was 6.6 ± 2.4 years. RESULTS: Subjects with remitting BP-I disorder in adolescent years had a significantly lower one-year prevalence of CD or ASPD compared to those with persistent BP-I disorder (χ2 = 10.35, p = 0.001). LIMITATIONS: Our inferences were derived from the examination of naturalistic longitudinal follow-up data and not results of a clinical trial. CONCLUSIONS: Results indicate that remission of manic symptoms at the adolescent follow up in youth with BP-I disorder were associated with a significant decrease in rates of CD/ASPD. These results suggest that targeting manic symptoms in youth with BP-I disorder could mitigate the course of CD/ASPD in youth. Considering the high morbidity and disability associated CD/ASPD in youth and the limited treatment options available to address it, if replicated, these findings would have very important clinical and public health significance.
Authors: Joseph Biederman; Michael C Monuteaux; Eric Mick; Thomas Spencer; Timothy E Wilens; Kristy L Klein; Julia E Price; Stephen V Faraone Journal: Biol Psychiatry Date: 2006-05-19 Impact factor: 13.382
Authors: R L Findling; N K McNamara; L A Branicky; M D Schluchter; E Lemon; J L Blumer Journal: J Am Acad Child Adolesc Psychiatry Date: 2000-04 Impact factor: 8.829
Authors: Timothy E Wilens; Joseph Biederman; Joel J Adamson; Aude Henin; Stephanie Sgambati; Martin Gignac; Robert Sawtelle; Alison Santry; Michael C Monuteaux Journal: Drug Alcohol Depend Date: 2008-03-17 Impact factor: 4.492
Authors: Joseph Biederman; Eric Mick; Janet Wozniak; Michael C Monuteaux; Maribel Galdo; Stephen V Faraone Journal: Biol Psychiatry Date: 2003-06-01 Impact factor: 13.382
Authors: J Wozniak; T Wilens; M DiSalvo; A Farrell; R Wolenski; S V Faraone; J Biederman Journal: Acta Psychiatr Scand Date: 2019-03-18 Impact factor: 6.392